Displaying drugs 1301 - 1325 of 2016 in total
ABBV-011
ABBV-011 is an antibody-drug conjugate of humanized, cysteine-engineered IgG1 monoclonal antibody targeting seizure-related 6 homolog conjugated to N-acetyl-gamma-calicheamicin.
Investigational
SLC-0111
Investigational
ABSK-091
Investigational
ASTX-029
ASTX-029 is under investigation in clinical trial NCT03520075 (Study of ASTX029 in Subjects With Advanced Solid Tumors).
Investigational
Somatropin pegol
Somatropin pegol is under investigation in clinical trial NCT00715689 (Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083).
Investigational
Parsaclisib
Parsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).
Investigational
Mirdametinib
PD-0325901 has been used in trials studying the treatment and basic science of Melanoma, Solid Tumour, Solid Tumors, Advanced Cancer, and Breast Neoplasms, among others.
Investigational
LL-37
LL-37 is a human cathelicidin that inhibits viral replication and while also playing a role in host defense against infection.
Investigational
Witch hazel
Nutraceutical
Matched Mixtures name: … HAMAZINC KREM ,60 G ... HAMEDERM PLUS %5,35 + %18 KREM, 60 GRAM …
Matched Products: … Camellia 60 Pure White Serum …
Matched Products: … Camellia 60 Pure White Serum …
SB-218078
SB-218078 is a specific inhibitor of CHK1.
Investigational
Matched Iupac: … 28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa …
GPI-0100
GPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the immune response.
The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy.
Investigational
IOWH-032
Iowh032 has been investigated for the treatment of Cholera, Diarrhea, and Secretory Diarrhea.
Investigational
GDC-0349
GDC-0349 has been used in trials studying the treatment of Non-Hodgkin's Lymphoma, Solid Tumor.
Investigational
GDC-0425
GDC-0425 is under investigation in clinical trial NCT01359696 (A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma).
Investigational
IQP-0528
IQP-0528 is under investigation in clinical trial NCT03082690 (ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study).
Investigational
CODA-001
CODA-001 is under investigation in clinical trial NCT01165450 (Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects).
Investigational
PCLX-001
PCLX-001 is a first-in-kind N-Myristoyltransferase (NMT) inhibitor being developed by Pacylex Pharmaceuticals (https://pacylex.com). Current studies have shown that PCLX-001 works differently than other known cancer drugs and has high activity and positive results in breast, lung, bladder and pancreas cancers.
Investigational
GDC-0134
Investigational
WSD-0922
Investigational
ETBX-041
Investigational
STRO-001
Investigational
AL-01211
Investigational
NGGT-002
NGGT-002 is a recombinant adeno-associated virus serotype 8 vector encoding human phenylalanine hydroxylase (PAH).
Investigational
M012
Investigational
Displaying drugs 1301 - 1325 of 2016 in total